1. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
- Author
-
Guo, Christina, Sharp, Adam, Gurel, Bora, Crespo, Mateus, Figueiredo, Ines, Jain, Suneil, Vogl, Ursula, Rekowski, Jan, Rouhifard, Mahtab, Gallagher, Lewis, Yuan, Wei, Carreira, Suzanne, Chandran, Khobe, Paschalis, Alec, Colombo, Ilaria, Stathis, Anastasios, Bertan, Claudia, Seed, George, Goodall, Jane, and Raynaud, Florence
- Abstract
Inflammation is a hallmark of cancer1. In patients with cancer, peripheral blood myeloid expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter survival and treatment resistance across malignancies and therapeutic modalities2–5. Whether myeloid inflammation drives progression of prostate cancer in humans remain unclear. Here we show that inhibition of myeloid chemotaxis can reduce tumour-elicited myeloid inflammation and reverse therapy resistance in a subset of patients with metastatic castration-resistant prostate cancer (CRPC). We show that a higher blood neutrophil-to-lymphocyte ratio reflects tumour myeloid infiltration and tumour expression of senescence-associated mRNA species, including those that encode myeloid-chemoattracting CXbibr2 ligands. To determine whether myeloid cells fuel resistance to androgen receptor signalling inhibitors, and whether inhibiting CXbibr2 to block myeloid chemotaxis reverses this, we conducted an investigator-initiated, proof-of-concept clinical trial of a CXbibr2 inhibitor (AZD5069) plus enzalutamide in patients with metastatic CRPC that is resistant to androgen receptor signalling inhibitors. This combination was well tolerated without dose-limiting toxicity and it decreased circulating neutrophil levels, reduced intratumour CD11b
+ HLA-DRlo CD15+ CD14− myeloid cell infiltration and imparted durable clinical benefit with biochemical and radiological responses in a subset of patients with metastatic CRPC. This study provides clinical evidence that senescence-associated myeloid inflammation can fuel metastatic CRPC progression and resistance to androgen receptor blockade. Targeting myeloid chemotaxis merits broader evaluation in other cancers.A translational study demonstrates the role of myeloid inflammatory cells in driving disease progression and treatment resistance in prostate cancer and shows that these cells can be targeted therapeutically. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF